Matrix metalloproteinase 7 (MMP-7) is a member of the MMP superfamily and is able to degrade extracellular matrix proteins such as casein, gelatin, fibronectin and proteoglycan. MMP-7 is a validated target for the development of small molecule drugs against cancer. MMP-13 is within the enzyme class the most efficient contributor to type II collagen degeneration and is a validated target in arthritis and cancer. We have developed the dual MMP-7/-13 inhibitor ZHAWOC6941 with IC50-values of 2.2 μM (MMP-7) and 1.2 μM (MMP-13) that is selective over a broad range of MMP isoforms. It spares MMP-1, -2, -3, -8, -9, -12 and -14, making it a valuable modulator for targeted polypharmacology approaches.
基质金属蛋白酶7(MMP-7)是MMP超家族的成员,能够降解胶乳蛋白、明胶、纤维连接蛋白和蛋白多糖等细胞外基质蛋白。MMP-7是癌症小分子药物开发的验证靶点。MMP-13在酶类中是对II型胶原的降解效率最高的贡献者,并且是关节炎和癌症的验证靶点。我们开发了双重MMP-7/-13抑制剂ZHAWOC6941,其IC50值分别为2.2μM(MMP-7)和1.2μM(MMP-13),在广泛的MMP亚型中具有选择性。它保留了MMP-1、-2、-3、-8、-9、-12和-14,使其成为针对性多药理学方法的有价值调节剂。